With the development of artificial intelligence technology, it plays an important role in laboratory medicine, especially in the automatic identification of cell morphology. The new generation of AI technology shows the characteristics of deep learning, autonomous learning, human-machine collaboration, and so on.

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

Naveris said Wednesday that Mayo Clinic began a Phase II trial of its circulating tumor DNA blood test, NavDx, to guide treatment for patients with HPV-driven head and neck cancer.

Agilent Technologies Inc. announced a strategic partnership with PathAI, a leading provider of AI-powered research tools and services for pathology, to deliver biopharmaceutical organizations a solution that combines Agilent’s assay development expertise and PathAI’s algorithm development capabilities.

On April 6, Sinocare released its annual report for 2022.

Avalon GloboCare and Qi Diagnostics on Tuesday announced their intention to co-develop a breathalyzer device for screening and the early detection of lung cancer.

Foundation Medicine said Tuesday that it has expanded an ongoing collaboration with Bristol Myers Squibb to include companion diagnostic development for the pharma firm's investigational tyrosine kinase inhibitor repotrectinib.

Righton Gene announced on April 9 that in 2022, the company achieved operating revenue of CNY 424 million, up 45.83% year-on-year; attributable net profit of CNY 40,473,600, down 14.49% year-on-year; basic earnings per share of CNY 0.73.

Ultima Genomics and Genome Insight said on Monday that they are collaborating to develop affordable whole-genome sequencing testing for cancer patients.

The UK National Health Service said last week that it would offer genetic testing for Lynch syndrome to all patients diagnosed with bowel and endometrial cancer.

On April 7, 2023, the "Molecular Diagnostics Joint Laboratory" jointly built by the Key Laboratory of Medical Molecular Virology of Fudan University, Ministry of Education/Health and Health Commission/ Academy of Medical Sciences and Liferiver Bio-Tech.

In a new study looking at the long-term effects of hospitalized patients who have acute kidney injury, Johns Hopkins Medicine researchers found that higher levels of certain biomarkers in urine and blood can predict a patient’s risk of developing chronic kidney disease.